Glaucoma Drops For Chronic Subretinal Fluid

In this interview from ASRS 2016, Dr. Jason Hsu discusses the results of his pilot study investigating topical glaucoma medication as an adjuvant therapy for patients with persistent retinal exudation despite frequent, regular anti-VEGF injections. After beginning twice-daily dorzolamide-timolol drops, all 10 patients showed a significant reduction in central subfield thickness, measured at the first follow-up visit (during their first regularly scheduled injection appointment after enrollment). This improvement was maintained to the last study visit. In addition, mean maximum subretinal fluid height decreased from 126.6 μm at baseline to 49.5 μm at the final visit (P = .02). Dr. Hsu hypothesizes that the drops enable the anti-VEGF medications to remain in the vitreous longer by decreasing outflow.